Demographics and disease characteristics for randomized patients and for transplanted recipients only
| . | Randomized patients . | Transplant recipients . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | Auto-SCT (n = 54) . | Allo-SCT (n = 49) . | Auto-SCT (n = 41*) . | Allo-SCT (n = 26) . | ||||
| Male | 31 | (57) | 34 | (69) | 28 | (68) | 17 | (65) |
| Female | 23 | (43) | 14 | (31) | 13 | (32) | 9 | (35) |
| Age, median (range) | 50 | (28, 60) | 50 | (24, 60) | 51 | (24, 60) | 50 | (35, 60) |
| LDH > Normal | 33 | (61) | 30 | (61) | 22 | (54) | 11 | (42) |
| ECOG > 1 | 11 | (20) | 10 | (20) | 8 | (20) | 5 | (19) |
| Stage III/IV | 47 | (87) | 44 | (90) | 36 | (88) | 23 | (88) |
| aaIPI 0 | 2 | (4) | 3 | (6) | 1 | (2) | 3 | (12) |
| aaIPI 1 | 22 | (41) | 16 | (33) | 20 | (49) | 10 | (38) |
| aaIPI 2 | 21 | (39) | 22 | (45) | 14 | (34) | 10 | (38) |
| aaIPI 3 | 9 | (17) | 8 | (16) | 6 | (15) | 3 | (12) |
| E-involvement | 32 | (59) | 31 | (63) | 24 | (59) | 15 | (58) |
| E > 1 | 16 | (30) | 17 | (35) | 11 | (27) | 6 | (23) |
| IPI 0 | 2 | (4) | 3 | (6) | 1 | (2) | 3 | (12) |
| IPI 1 | 16 | (30) | 10 | (20) | 14 | (34) | 7 | (27) |
| IPI 2 | 22 | (41) | 21 | (43) | 16 | (39) | 11 | (42) |
| IPI 3 | 9 | (17) | 11 | (22) | 9 | (22) | 4 | (15) |
| IPI 4 | 5 | (9) | 4 | (8) | 1 | (2) | 1 | (4) |
| Bulky disease | 10 | (19) | 7 | (14) | 8 | (20) | 3 | (12) |
| B-symptoms | 32 | (59) | 29 | (59) | 23 | (56) | 16 | (62) |
| Bone marrow involved | 17 | (31) | 15 | (31) | 7 | (17) | 9 | (35) |
| Histology | ||||||||
| Reviewed | 54† | (100) | 46 | (94) | 41‡ | (100) | 25 | (96) |
| Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) | 16 | (30) | 15 | (33) | 11 | (27) | 8 | (32) |
| Angioimmunoblastic T-cell lymphoma | 17 | (33) | 20 | (43) | 16 | (40) | 12 | (48) |
| Anaplastic large cell lymphoma ALK-negative | 9 | (17) | 5 | (11) | 8 | (20) | 3 | (12) |
| Extranodal NK/T-cell lymphoma, nasal type | 0 | (0) | 1 | (2) | 0 | (0) | 0 | (0) |
| Enteropathy-associated T-cell lymphoma (EATL) types I and II | 3 | (6) | 0 | (0) | 3 | (8) | 0 | (0) |
| Hepatosplenic T-cell lymphoma | 2 | (4) | 1 | (2) | 1 | (2) | 1 | (4) |
| Subcutaneous panniculitis-like PTCL | 1 | (2) | 0 | (0) | 0 | (0) | 0 | (0) |
| Primary cutaneous γ/δ T-cell lymphoma | 0 | (0) | 1 | (2) | 0 | (0) | 0 | (0) |
| T-cell lymphoma, further specification not possible | 1 | (2) | 1 | (2) | 1 | (2) | 1 | (4) |
| Other entities | 3§ | (6) | 2|| | (4) | 0 | (0) | 0 | (0) |
| . | Randomized patients . | Transplant recipients . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | Auto-SCT (n = 54) . | Allo-SCT (n = 49) . | Auto-SCT (n = 41*) . | Allo-SCT (n = 26) . | ||||
| Male | 31 | (57) | 34 | (69) | 28 | (68) | 17 | (65) |
| Female | 23 | (43) | 14 | (31) | 13 | (32) | 9 | (35) |
| Age, median (range) | 50 | (28, 60) | 50 | (24, 60) | 51 | (24, 60) | 50 | (35, 60) |
| LDH > Normal | 33 | (61) | 30 | (61) | 22 | (54) | 11 | (42) |
| ECOG > 1 | 11 | (20) | 10 | (20) | 8 | (20) | 5 | (19) |
| Stage III/IV | 47 | (87) | 44 | (90) | 36 | (88) | 23 | (88) |
| aaIPI 0 | 2 | (4) | 3 | (6) | 1 | (2) | 3 | (12) |
| aaIPI 1 | 22 | (41) | 16 | (33) | 20 | (49) | 10 | (38) |
| aaIPI 2 | 21 | (39) | 22 | (45) | 14 | (34) | 10 | (38) |
| aaIPI 3 | 9 | (17) | 8 | (16) | 6 | (15) | 3 | (12) |
| E-involvement | 32 | (59) | 31 | (63) | 24 | (59) | 15 | (58) |
| E > 1 | 16 | (30) | 17 | (35) | 11 | (27) | 6 | (23) |
| IPI 0 | 2 | (4) | 3 | (6) | 1 | (2) | 3 | (12) |
| IPI 1 | 16 | (30) | 10 | (20) | 14 | (34) | 7 | (27) |
| IPI 2 | 22 | (41) | 21 | (43) | 16 | (39) | 11 | (42) |
| IPI 3 | 9 | (17) | 11 | (22) | 9 | (22) | 4 | (15) |
| IPI 4 | 5 | (9) | 4 | (8) | 1 | (2) | 1 | (4) |
| Bulky disease | 10 | (19) | 7 | (14) | 8 | (20) | 3 | (12) |
| B-symptoms | 32 | (59) | 29 | (59) | 23 | (56) | 16 | (62) |
| Bone marrow involved | 17 | (31) | 15 | (31) | 7 | (17) | 9 | (35) |
| Histology | ||||||||
| Reviewed | 54† | (100) | 46 | (94) | 41‡ | (100) | 25 | (96) |
| Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) | 16 | (30) | 15 | (33) | 11 | (27) | 8 | (32) |
| Angioimmunoblastic T-cell lymphoma | 17 | (33) | 20 | (43) | 16 | (40) | 12 | (48) |
| Anaplastic large cell lymphoma ALK-negative | 9 | (17) | 5 | (11) | 8 | (20) | 3 | (12) |
| Extranodal NK/T-cell lymphoma, nasal type | 0 | (0) | 1 | (2) | 0 | (0) | 0 | (0) |
| Enteropathy-associated T-cell lymphoma (EATL) types I and II | 3 | (6) | 0 | (0) | 3 | (8) | 0 | (0) |
| Hepatosplenic T-cell lymphoma | 2 | (4) | 1 | (2) | 1 | (2) | 1 | (4) |
| Subcutaneous panniculitis-like PTCL | 1 | (2) | 0 | (0) | 0 | (0) | 0 | (0) |
| Primary cutaneous γ/δ T-cell lymphoma | 0 | (0) | 1 | (2) | 0 | (0) | 0 | (0) |
| T-cell lymphoma, further specification not possible | 1 | (2) | 1 | (2) | 1 | (2) | 1 | (4) |
| Other entities | 3§ | (6) | 2|| | (4) | 0 | (0) | 0 | (0) |
Data are expressed as number of patients (percentage of total group).
Seven patients randomized to allo-SCT are included.
Two patients and ‡1 patient without definitive diagnosis (PTCL suspected; no definite diagnosis possible).
T-cell histocyte-rich large B-cell lymphoma; histiocytic sarcoma; classic Hodgkin lymphoma.
Lymph node infiltration by primary cutaneous T-cell lymphoma (e.g., mycosis fungoides); Epstein-Barr+ CD30+ lymphoproliferation.